The initial results for the oral, iron-based drug were both statistically significant and clinically meaningful, the company said.
Based on the study of patients who had not adequately responded to or were unable to tolerate current oral iron therapies, Keryx said it would apply in the third quarter for an expanded approval with U.S. regulators for ferric citrate in moderate to advanced chronic kidney patients not dependent on dialysis.
The drug was previously approved under the brand name Auryxia to lower the amount of phosphate in the blood of chronic kidney disease patients on dialysis.
An estimated 1.6 million people in the United States suffer from stage 3 to stage 5 non-dialysis dependent chronic kidney disease and iron deficiency anemia, Keryx said.
Side effects were primarily mild to moderate and included diarrhea, constipation and nausea. Twelve of 31 ferric citrate patients who discontinued treatment did so because of side effects, the company reported.
Two patients in the drug group died during the study, but researchers deemed those deaths to be unrelated to the treatment.
The drug also met secondary goals of the trial compared with placebo, including mean change in hemoglobin and proportion of patients with a durable response, Keryx reported.
"We believe that the ability to treat iron deficiency anemia, managing hemoglobin and iron levels, could have an important effect on the way kidney specialists treat these patients," Keryx Chief Medical Officer John Neylan said in a statement.
More about:
